Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 14, 1998

View Archived Issues

Micrologix Biotech advances development of antimicrobial peptides for treatment of eye infections

New anticonvulsant option now available in U.K.

Synthelabo compounds act as 5-HT receptor ligands

Glaxo Wellcome receives first marketing approval for new asthma therapeutic

Heart valve abnormalities a problem among appetite suppressant-treated obese patients

Inhibitors of sPLA2 claimed by Lilly for septic shock, etc.

Preparation and use of peptide bradykinin B2 receptor agonists described by Fournier

Antiplatelet compounds developed by Merck & Co.

Inhibitors of ICE activity described by Vertex

Orally active anticoagulants in early development at Gedeon Richter

Antisense oligodeoxynucleotide to rat ICAM-1 tested in rat model of enterocolitis

Neuroprotective effects of S-12024-2 demonstrated in rat model of neurodegeneration

Japanese researchers report progress in the gene therapy of gastric cancer

Antiasthma drug can be used safely in combination with anticonvulsants

Role of oral porcine spasmolytic polypeptide in GI disorders studied by Danish group

Roche to withdraw support for development of Kyowa Hakko's antiparkinsonian

Nateglinide preclinical and clinical data featured at diabetes meeting

Phase II trial of revolutionary migraine treatment completed ahead of schedule

Celgene successfully completes phase I multiple-dose trial of lead SelCID compound

Company Profile: Xcyte Therapies

FDA approves, HMR begins shipping new treatment for adult rheumatoid arthritis

Development of MGDF discontinued at Amgen

Phase II testing of ISV-205 begins for glaucoma

Early clinical trial results reported for cilansetron at recent congress

AEterna releases interim phase I/II data for Psovascar

Licensing opportunity from RCT: use of cobalamins to control excess nitric oxide

Lodensine cleared for phase II trials in HIV patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Hippocratic loath? ‘Harm’ threat from ACIP’s proposed HBV shift
BioWorld
Individual liberty and choice vs. wider public health became one predictable hinge upon which swung the often-acerbic debates at the CDC’s Advisory Committee for...
Høeg appointment as acting CDER director tied to vaccine strategy?
BioWorld
After a more than 13-year period of stability with Janet Woodcock as the head of CDER, with Patrizia Cavazzoni taking charge during the next four years of former...
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...